Merck KGaA
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Kai Beckmann
- Full Time Employees
- 62,461
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Frankfurter Strasse 250 Darmstadt HE Germany 64293
- IPO Date
- Oct 20, 1995
- Website
- merckgroup.com
- Similar Companies
- Business
- Merck KGaA engages in the discovery, development, manufacturing, and marketing of products for healthcare, life sciences, and electronics markets worldwide. The company operates through three main business sectors: Healthcare, which offers prescription medicines for oncology, neurology, immunology, fertility, and endocrinology; Life Science, providing tools, technologies, and services for biopharmaceutical research, development, and manufacturing including process development, filtration, chromatography, and single-use systems; and Electronics, supplying materials for semiconductor, display, and surface technologies such as liquid crystals, photoresists, OLED materials, and deposition systems. Merck KGaA maintains a global presence with operations in over 60 countries, serving pharmaceutical companies, biotech firms, academic institutions, and industrial manufacturers as primary customers. Founded in 1668 and headquartered in Darmstadt, Germany, the company traces its roots as one of the world's oldest pharmaceutical and chemical firms, with subsidiaries including MilliporeSigma in the U.S. for life sciences and Versum Materials prior to its divestiture. In recent developments, Merck KGaA completed the acquisition of BioReliance in 2024 to bolster its bioprocessing services portfolio and formed a strategic alliance with Sandoz in 2025 for biosimilars co-development and commercialization in oncology; additionally, it launched the next-generation Erez™ platform for gene therapy manufacturing and expanded its electronics business through a €1.2 billion investment in a new OLED materials facility in Japan.
Company News
Germany's Merck to Buy U.K. Biotech Silence Therapeutics for $1.3 Billion
Merck KGaA (OTCMKTS:MKGAF) Shares Gap Down – Should You Sell?
Merck KGaA (OTCMKTS:MKKGY) versus MediciNova (NASDAQ:MNOV) Head-To-Head Contrast
Merck KGaA (OTCMKTS:MKKGY) Shares Shorted: Short Interest Up 95.4% in September
Merck KGaA (OTCMKTS:MKKGY) Receives Consensus Rating of “Hold” from Brokerages
363,066 Shares in Merck KGaA $MKGAF Purchased by Beacon Pointe Advisors LLC
Blue Edge Capital LLC Decreases Stake in Merck KGaA $MKGAF
Bamco Inc. NY Buys Shares of 22,000 Merck KGaA $MKGAF
ADAR1 Capital Management LLC Invests $403,000 in Merck KGaA $MKGAF
Ancora Advisors LLC Invests $2.69 Million in Merck KGaA $MKGAF
Ausdal Financial Partners Inc. Takes Position in Merck KGaA $MKGAF
AFT Forsyth & Company Inc. Invests $822,000 in Merck KGaA $MKGAF
7,331,418 Shares in Merck KGaA $MKGAF Purchased by Barrow Hanley Mewhinney & Strauss LLC
Barbara Oil Co. Makes New Investment in Merck KGaA $MKGAF
Ally Financial Inc. Takes $4.50 Million Position in Merck KGaA $MKGAF
Emerald Investment Advisers LLC Makes New Investment in Merck KGaA $MKGAF
B. Metzler seel. Sohn & Co. AG Takes Position in Merck KGaA $MKGAF
Bell & Brown Wealth Advisors LLC Invests $5.66 Million in Merck KGaA $MKGAF
August Group Capital Ltd Takes Position in Merck KGaA $MKGAF
9,092 Shares in Merck KGaA $MKGAF Acquired by Asahi Life Asset Management CO. LTD.